ClinConnect ClinConnect Logo
Search / Trial NCT01906359

Effects of Triacylglycerol Structure on Gut Hormones and Haemostatic Markers

Launched by MALAYSIA PALM OIL BOARD · Jul 19, 2013

Trial Information

Current as of July 21, 2025

Completed

Keywords

Interesterified Fat Stereospecific Number 2 Gut Hormones Gip Insulin Sensitivity Postprandial Lipaemia Haemostatic Markers

ClinConnect Summary

Subjects aged between 30 and 60 years old (male and female) with Type 2 diabetes mellitus (T2DM) will be recruited for this study. A randomized, crossover, double-blind study design will be carried out to investigate the acute effects of high fat meals prepared using palm olein (PO), chemically interesterified palm olein (IPO) and high oleic sunflower oil (HOS) (control) on study subjects with T2DM. Study subjects will have to undergo three postprandial challenges, separated by at least one week interval. Fasting blood sample and duplicate baseline blood samples will be taken in the morning...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Mild T2DM individuals not planned for medical intervention
  • 7.0 mmol/L ≤ fasting glucose ≤ 11.1 mmol/L
  • 6.5% ≤ HbA1c ≤ 9.0%
  • Not using antihypertensive, lipid lowering, insulin/glucose modulating medication
  • 2. Mild T2DM individuals currently on medical intervention
  • Fasting glucose ≤ 11.1 mmol/L
  • HbA1c ≤ 9.0%
  • Using antihypertensive, lipid lowering or glucose modulating medication
  • 3. Malaysian male or female with T2DM aged between 30 to 60 years old
  • 4. Not using insulin
  • 5. Not having any complications of diabetes
  • 6. No medical history of myocardial infarction, angina, thrombosis, stroke or cancer
  • 7. Haemoglobin levels for females ≥ 11.5 gm/dl and males ≥ 12.5 gm/dl
  • 8. Serum ferritin \> 15 µg/l at commencement of study
  • Exclusion Criteria:
  • 1. Medical history of myocardial infarction, angina, thrombosis, stroke or cancer
  • 2. Underweight (BMI \< 18.5 kg/m²)
  • 3. Using insulin
  • 4. Total cholesterol \> 7.0 mmol/L
  • 5. Abnormal liver function, renal function and haematology
  • 6. Hypersensitive towards heparin
  • 7. Gastric or lactose intolerance
  • 8. Smoker
  • 9. Pregnancy and lactating
  • 10. Taking alcohol
  • 11. Taking alcohol
  • 12. Haemoglobin levels for females ≤ 11.5 gm/dl and males ≤ 12.5 gm/dl
  • 13. Serum ferritin \< 15 µg/l at commencement of study

About Malaysia Palm Oil Board

The Malaysia Palm Oil Board (MPOB) is a leading government agency dedicated to the promotion and development of the palm oil industry in Malaysia. With a focus on research and innovation, MPOB aims to enhance the productivity, sustainability, and global competitiveness of palm oil through comprehensive scientific studies and clinical trials. By collaborating with various stakeholders, including industry players, researchers, and policymakers, MPOB strives to address health, environmental, and economic challenges associated with palm oil production, ensuring that the industry meets both local and international standards for quality and sustainability.

Locations

Kajang, Selangor, Malaysia

Kajang, Selangor, Malaysia

Sepang, Selangor, Malaysia

Serdang, Selangor, Malaysia

Shah Alam, Selangor, Malaysia

Patients applied

0 patients applied

Trial Officials

Kim Tiu Teng, PhD

Principal Investigator

Malaysian Palm Oil Board (MPOB)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials